Skip to main content
Breast Cancer Research : BCR logoLink to Breast Cancer Research : BCR
. 2008 May 13;10(Suppl 2):P77. doi: 10.1186/bcr1961

C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target

E Katz 1, D Faratian 1, JMS Bartlett 1, K MacLeod 1, H Pedersen 1, A Larionov 1, EM Smith 2, AP Howell 2, JM Dixon 1, EE Evans 2, SP Langdon 1, DJ Harrison 1
PMCID: PMC3300780

C35 is a protein overexpressed in invasive breast cancer. The C35 gene is located on chromosome 17, next to ERBB2/HER2. C35 encodes a canonical immunoreceptor tyrosine-based activation motif (ITAM) sequence. ITAM-containing proteins have key signalling roles in the hematopoietic system and in oncogenic retroviruses. The ITAM interacts with Syk kinase, which mediates downstream signalling events.

C35-overexpressing breast tumours were found to be of two subsets. In one subset, C35 is coexpressed with HER2. The second subset is found within the basal-like carcinoma group. In order to evaluate the therapeutic potential of targeting C35 ITAM/Syk signalling, we utilised 3D cell cultures. Transformed cell lines act in a manner resembling their in vivo behaviour when grown in 3D cultures, on reconstituted basement membrane. Using this method, C35-expressing cells formed enlarged structures in both an ITAM-dependent and Syk-dependent manner. Furthermore, BT474 cells coexpressing C35 and HER2 formed more normal 3D structures when treated with a combination of Herceptin and Syk inhibitors.


Articles from Breast Cancer Research : BCR are provided here courtesy of BMC

RESOURCES